Categories Uncategorized

Local Legislators in Massachusetts Unanimously Vote to Decriminalize Psychedelics

Last week, local legislators in Massachusetts unanimously confirmed their support for a resolution that would decriminalize various psychedelics. The Somerville City Council heard the testimony of two individuals who had benefitted personally from the use of psychedelics therapeutically before approving the measure in a 9-0 vote. This measure was also backed by the mayor.

In addition to this, some council members debated the possible medical value of psychedelic substances, especially in mental health issues, as well as the failures of the drug war.

In a written statement to legislators, the Heroic Hearts Project, Bay Staters for Natural Medicines and Decriminalize Nature declared that by decriminalizing entheogenic substances, the state could make harm-reduction strategies the norm as health-care providers and therapists adopted these plants for spiritual, psychological and physical relief.

The organizations also stated that Somerville had the chance to not only put public health above imprisoning individuals in cases of abuse of controlled substances and addiction but also allow loved ones, neighbors and friends to seek the spiritual and physical relief that they require.

Under the approved measure, the enforcement of laws against psychedelics such as ayahuasca and psilocybin mushrooms would be among the city’s lowest priorities. The measure also requested that the county prosecutor stop pursuing cases for individuals who had been charged with distribution or possession of entheogens.

The resolution states that no employee, officer, commission, board, agency or department in the City of Somerville, including employees of the Somerville Police Department, should utilize any resources or funds of the city to help in the enforcement of laws that impose criminal penalties for the possession and use of psychedelic plants by adults.

Apart from this, the measure also highlights that the city would not permit the commercial sales of these entheogenic substances nor would it allow driving under the influence of the said substances.

At the end of the meeting, city council president Matt McLaughlin stated that he loved living in a city where the agenda in question was not controversial and received undivided support.

Additionally, the vote of approval allows Somerville to join other cities across the country that have also ratified psychedelics decriminalization. The first jurisdiction to decriminalize psychedelic substances was Washington, DC, through last year’s November ballot. Other cities that have also decriminalized the possession of fungi and plant-based psychedelics include Ann Arbor, Michigan; and Santa Cruz and Oakland, both in California.

Last year’s November election also saw Oregon become the first state in the United States to legalize the use of psilocybin mushrooms for therapeutic purposes.

In neighboring Canada, Cybin Inc. (NEO: CYBN) is on course to benefit from the $25 billion legal supplements market through its range of products made from fungi.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago